Predicted protein targets (top 2)
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Defoslimod SCHEMBL13752580 | 1.00 | TLR4 (0.75) | TLR4LY96 | |
| Defoslimod SCHEMBL13231311 | 1.00 | TLR4 (0.75) | TLR4LY96 | |
| SCHEMBL8209575 | 1.00 | TLR4 (0.75) | TLR4LY96 | |
| Defoslimod SCHEMBL3714038 | 1.00 | TLR4 (0.75) | TLR4LY96 | |
| Defoslimod SCHEMBL12469694 | 1.00 | TLR4 (0.75) | TLR4LY96 | |
| Defoslimod SCHEMBL132545 | 1.00 | TLR4 (0.75) | TLR4LY96 | |
| Defoslimod SCHEMBL13705691 | 1.00 | TLR4 (0.75) | TLR4LY96 | |
| SCHEMBL8208245 | 1.00 | TLR4 (0.75) | TLR4LY96 | |
| Defoslimod SCHEMBL19839002 | 1.00 | TLR4 (0.75) | TLR4LY96 | |
| SCHEMBL8209574 | 1.00 | TLR4 (0.75) | TLR4LY96 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090214669-A1 | Combination anticancer therapy and pharmaceutical compositions therefore | OM PHARMA (CH) | 2009-08-27 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090214669-A1 | Combination anticancer therapy and pharmaceutical compositions therefore | LCK, BMX, YES1 | TLR4 1370/4885LY96 632/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.